A- A A+

Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment. 

Specka M, Kuhlmann T, Sawazki J, et al. 

Front Psychiatry. 2020;11:569. Published 2020 Jul 7. doi:10.3389/fpsyt.2020.00569


The Role of Dopamine in the Stimulant Characteristics of Novel Psychoactive Substances (NPS) - Neurobiological and Computational Assessment Using the Case of Desoxypipradrol (2-DPMP). 

Loi B, Sahai MA, De Luca MA, Shiref H, Opacka-Juffry J. 

Front Pharmacol. 2020;11:806. Published 2020 Jun 5. doi:10.3389/fphar.2020.00806

The Role of Dopamine in the Stimulant Characteristics of Novel Psychoactive Substances (NPS) - Neurobiological and Computational Assessment Using the Case of Desoxypipradrol (2-DPMP). 

Heroin Adulterated with the Novel Synthetic Cannabinoid, 5F-MDMB-PINACA: A Case Series. 

Ershad M, Dela Cruz M, Mostafa A, Khalid MM, Arnold R, Hamilton R. 

Clin Pract Cases Emerg Med. 2020;4(2):121‐125. Published 2020 Apr 23. doi:10.5811/cpcem.2020.2.45060


EMCDDA technical report on the new psychoactive substance N,Ndiethyl- 2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene)


The purpose of this technical report is to provide an analysis of the available information on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (commonly known as isotonitazene), an opioid analgesic that has recently emerged on the drug market in Europe, to support a risk assessment of the substance that has been requested by the European Commission in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended). (EMCDDA, Lissabon, Juni 2020)


EMCDDA initial report on the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene)


Isotonitazene is a synthetic opioid analgesic monitored by the EMCDDA as a new psychoactive substance through the European Union Early Warning System since 2019. Based on potential public health risks, an initial report has been prepared and submitted to the Commission and the Member States, in accordance with Article 5b of Regulation (EC) No 1920/2006 (as amended). Its purpose is to provide scientific evidence to the Commission to allow it to make an informed decision regarding whether or not there is a need to request a risk assessment on a new psychoactive substance. (EMCDDA, Lissabon, April 2020)


Psychedelic Medicine - Hacking Psychiatry?! (Video)

Psychedelic Therapy as a fundamentally new approach to mental health issues Psychedelic research constitutes a challenge to the current paradigm of mental healthcare. But what makes it so different? And will it be able to meet the high expectations it is facing? This talk will provide a concise answer. Psychedelic Therapy is evolving to be a game changer in mental healthcare. Where classical antidepressants and therapies e.g. for Posttraumatic Stress Disorder often have failed to provide relief, substance assisted psychotherapies with Psilocybin, LSD and MDMA show promising results in the ongoing clinical trials worldwide. A challenge to the current paradigm: Unlike the conventional approach of medicating patients with antidepressants and other psychotropic drugs on a daily basis for months and years at a time, Psychedelic Therapy offers single applications of psychedelics or emotionally opening substances such as Psilocybin, LSD and MDMA within the course of a limited number of therapeutic sessions. The clinical trials conducted in this kind of setting are currently designed around depression, substance abuse, anxiety and depression due to life threatening illnesses, PTSD, anorexia and social anxiety in Autism. Though the results look promising, it is important not to take these therapies for a “magic bullet cure” for all and very patient will mental issues. This talk will outline the principles of psychedelic therapy and research and provide a concise overview of what psychedelic therapy can and cannot offer in the future. Andrea Jungaberle

(36C3 – Jahreskongress des CCC - Chaos Computer Club, 28.12.2019, Video, 36:42)


UNODC. Current NPS Threats – Volume II (January 2020)

UNODC Early Warning Advisory Toxicology Highlights

Poly-drug use continues to feature highly in cases of fatalities associated

with NPS.

Benzodiazepine-type NPS are increasingly reported in cases of driving

under the influence of drugs in some countries.

Incidents of kratom identification in poly-drug use cases are increasingly

reported in a number of countries


New psychoactive substances (NPS) in the Netherlands: occurrence in forensic drug samples, consumer drug samples and poisons center exposures between 2013 and 2017.

Hondebrink, L., Nugteren‐van Lonkhuyzen, J. J., Hunault, C. C., van den Berg, J., van der Gouwe, D., and van Riel, A. J. H. P. ( 2020) 



USA. Johns Hopkins Scientists Give Psychedelics the Serious Treatment

The first research center of its kind in the country is bringing renewed rigor to the investigation of the drugs’ therapeutic uses. (Scientific American, USA, 16.01.2020)


New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard.

Zaami S.

Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9681-9690. doi: 10.26355/eurrev_201911_19529.


Polysubstance use patterns and novel synthetics: A cluster analysis from three U.S. cities.

Elliott L, Haddock CK, Campos S, Benoit E (2019) 

PLoS ONE 14(12): e0225273. doi.org/10.1371/journal.pone.0225273


EMCDDA. EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances


These guidelines provide the rationale, steps, procedures, roles, and responsibilities for the operation of the EU Early Warning System. They reflect the requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) with respect to information exchange and the early warning system, as well as for the initial report, risk assessment, and control measures.

These guidelines are accompanied by Guidance notes, see the full list below. (EMCDDA, Lissabon, Dezember 2019 )


The health threat of drugs of abuse adulteration by new psychoactive substances.

Minutillo A, Palmi I, Mastrobattista L.

Clin Ter. 2019 Nov-Dec;170(6):e425-e426. doi: 10.7417/CT.2019.2170.


DHS. Neue psychoaktive Substanzen (NPS) 

Die Sucht und ihre Stoffe: Eine Informationsreihe über die gebräuchlichsten Drogen und Suchtsubstanzen. (DHS – Deutsche Hauptstelle für Suchtfragen, 2019)


Mapping novel psychoactive substances policy in the EU: The case of Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and Sweden.

Neicun J, Steenhuizen M, van Kessel R, Yang JC, Negri A, Czabanowska K, et al. (2019) 

PLoS ONE 14(6): e0218011. doi.org/10.1371/journal.pone.0218011


Impact of Novel Psychoactive Substances on Clinical and Forensic Toxicology and Global Public Health.

Huestis MA, Brandt SD, Rana S, Auwärter V, Baumann MH.

Clin Chem. 2017 Oct;63(10):1564-1569. doi: 10.1373/clinchem.2017.274662. Epub 2017 Jun 30.


United Nations Toolkit on Synthetic Drugs

UNODC, WHO, INCB, März 2019


UNODC launches toolkit on synthetic drugs to support Member States in addressing challenges

UNODC today launched the United Nations (UN) Toolkit on Synthetic Drugs, a web-based platform with a wide range of electronic resources that offer innovative and practical tools on how to approach challenges related to synthetic drugs and particularly opioids. (UNODC, Wien, 18.03.2019)


March 2019 - UNODC Laboratory: Current NPS Threats, a new publication, presents highlights from the UNODC Toxicology Portal

VIENNA, Austria.The first volume of the new biannual Current NPS Threats was launched with data reported to the Toxicology Portal (Tox-Portal) of the UNODC Early Warning Advisory on NPS. These data from post-mortem, clinical and other casework were reported by toxicology laboratories from 29 countries in all regions of the world and allowed to identify some key recent developments regarding health threats posed by NPS. 

- Synthetic cannabinoids, synthetic opioids and stimulants account for the majority of NPS reported to the Tox-Portal
- Synthetic cannabinoids, in particular remain harmful, persistent and prevalent with more reports in 2018 than synthetic opioids
- Poly-drug use continues to be a factor and an important consideration in NPS fatalities
- Benzodiazepine-type NPS feature highly in driving under the influence of drugs.

The Tox-Portal is an online tool developed in collaboration with The International Association of Forensic Toxicologists (TIAFT) that collects data on toxicology and harm related to the use of NPS at a global level. (UNODC Laboratory, März 2019)



Auf den folgenden Seiten finden Sie Informationen zu den getesteten Produkten. Die Informationen sind grundsätzlich mit Vorsicht zu benutzen und sollen Ihnen einen Überblick verschaffen, was enthalten sein könnte, wobei man immer beachten muss, dass sich die Inhaltsstoffe wieder verändern können. (BAS!S - Beratung, Arbeit, Jugend & Kultur e.V., Frankfurt/M.)


The long tail of a demon drug: The 'bath salts' risk environment.

Elliott L, Benoit E, Campos S, Dunlap E.

Int J Drug Policy. 2018 Jan;51:111-116. doi: 10.1016/j.drugpo.2017.10.007. 


Europa. Europe gets stronger system to tackle new psychoactive substances: New legislation, bringing faster response to new drugs, applies from today

Europe’s ability to rapidly respond to public health and social threats caused by new psychoactive substances (NPS/‘new drugs’) will be significantly strengthened, thanks to new legislation applying from today (1).

The legislation — applicable across Europe from 23 November 2018 — strengthens the EU Early Warning System (EU EWS) and risk assessment procedures on NPS and shortens control processes. The legislation comes in response to the recent growth in the availability of NPS and follows proposals from the European Commission (EC). (EMCDDA, Lissabon, 23.11.2018)


UK. Public Health England: up-to-date overview of new and emerging drug-related health harms in just three pages

We collate information here about the reported effects of new psychoactive substances (NPS) and other drugs. Information comes from a range of intelligence sources (including RIDR) to support frontline practitioners, service providers and other stakeholders in responding to new and emerging health harms. (PHE, November 2018)


UNODC. NPS Poster 

This poster provides a brief overview of the pharmacological effect groups of new psychoactive substances (NPS). (UNODC, März 2018)


Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures.

Evans-Brown M., Sedefov R. (2018) 

In: . Handbook of Experimental Pharmacology. Springer, Berlin, Heidelberg, doi.org/10.1007/164_2018_160 


USA/ N-Ethylpentylone. DEA acts against dangerous, deadly designer synthetic drug linked to 151 overdose deaths since 2015

WASHINGTON – The Drug Enforcement Administration today announced action against a dangerous designer synthetic cathinone linked to 151 overdose deaths in the United States between 2015 and 2018. (DEA, 31.08.2018)


Europa. EMCDDA–Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA - ISSN 1977-7841 -- In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances


This report presents the key activities performed by the EMCDDA and Europol in 2017 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, including new psychoactive substances notified in 2017, Joint Reports produced, risk assessments conducted and public health-related alerts and advisories issued to the EU Early Warning System Network. (EMCDDA,Europol,Lissabon,August 2018)


New Psychoactive Substances: A Guide for Pharmacists

A. Guirguis1, C. Bond2, G. Hawksworth2 , J. Lawrence2  and L. Martini2

1Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, University of Hertfordshire, UK.

2Science and Research Board, Royal Pharmaceutical Society, UK.


USA/Deutschland. Data-Sharing Website May Speed Response to New Illegal Drugs - The ‘NPS Data Hub’ will help forensic chemists identify new types of fentanyl and other narcotics more quickly.

The drug overdose epidemic currently gripping the nation is so tenacious in part because it’s being driven by fentanyl, a synthetic opioid that comes in many forms. Each form has a slightly different chemical structure, and clandestine chemists are constantly cooking up new ones. From a law-enforcement perspective, this makes fentanyl a moving target and very difficult to control.

To help with this situation, scientists at the National Institute of Standards and Technology (NIST), the German Federal Criminal Police Office (the Bundeskriminalamt, or BKA) and the U.S. Drug Enforcement Agency have launched a website where forensic chemists can share data on new drug variants, also called drug analogs. Described in Forensic Chemistry, the NPS Data Hub (NPS stands for Novel Psychoactive Substances) includes the chemical structures of drug analogs and their chemical signatures, which are the keys to identifying them in the lab. (National Institute of Standards and Technology (NIST), USA, 05.07.2018)


Mind your Trip

Neue psychoaktive Substanzen (NPS) sind weitestgehend unerforscht. Über Wirkungen und vor allem (langfristige) Nebenwirkungen ist nur sehr wenig bis gar nichts bekannt. Viele dieser Rauschmittel sind für den Eigengebrauch legal. Sie sind aber nicht ungefährlich! Mind Your Trip hilft dir, deinen NPS-Konsum zu überprüfen. Gemeinsam mit Fachleuten bieten wir unterschiedliche Möglichkeiten an, um deinen Konsum dieser Substanzen zu kontrollieren. (mindyourtrip.eu, 2018)